Rare diseases
Investigational molecules
Locations
13-1 Songdo-Dong, 22014
Celltrion Inc. includes type 2 diabetes mellitus within its clinical research portfolio, with interest in treatment strategies for patients who have inadequate glycemic control despite established oral therapy. The sponsor’s work in this area reflects attention to combination approaches involving antihyperglycemic agents and broader management of metabolic disorders.
Its diabetes-focused studies align with ongoing interest in improving treatment options for chronic endocrine and metabolic disease.
Celltrion Inc. runs clinical trials in conditions such as Psoriasis, Rheumatoid arthritis, Multiple sclerosis, Plasma cell myeloma refractory, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Study Comparing CT-P55 and Secukinumab for Moderate to Severe Plaque Psoriasis Patients
PolandStudy on the Effectiveness and Safety of CT-P13 for Patients with Moderate to Severe Rheumatoid Arthritis
PolandStudy Comparing CT-P53 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis
BulgariaComparing CT-P44 and Darzalex Faspro with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma
PolandStudy Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer
CroatiaStudy on the Effectiveness and Safety of Adding Pioglitazone to Metformin and Empagliflozin for Patients with Type 2 Diabetes with Poor Blood Sugar Control
PolandIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
